IDEAYA Biosciences Inc IDYA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if IDYA is a good fit for your portfolio.
News
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
-
IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
-
IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
-
IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
-
IDEAYA Biosciences to Participate in Upcoming February 2024 Investor Relations Events
-
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
IDEAYA Biosciences Gets Fast-Track Designation for IDE161 for Breast Cancer
Trading Information
- Previous Close Price
- $41.17
- Day Range
- $39.81–41.45
- 52-Week Range
- $14.33–47.74
- Bid/Ask
- $16.07 / $63.87
- Market Cap
- $3.00 Bil
- Volume/Avg
- 496,442 / 763,997
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 101.27
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 124
- Website
- https://www.ideayabio.com
Comparables
Valuation
|
Metric
|
IDYA
|
PRLD
|
CGEM
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 4.31 | 0.97 | 1.64 |
Price/Sales | 101.27 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
IDYA
PRLD
CGEM
Financial Strength
|
Metric
|
IDYA
|
PRLD
|
CGEM
|
|---|---|---|---|
Quick Ratio | 19.38 | 10.67 | 16.60 |
Current Ratio | 19.65 | 10.79 | 17.07 |
Interest Coverage | — | — | — |
Quick Ratio
IDYA
PRLD
CGEM
Profitability
|
Metric
|
IDYA
|
PRLD
|
CGEM
|
|---|---|---|---|
Return on Assets (Normalized) | −19.18% | −38.93% | −24.60% |
Return on Equity (Normalized) | −20.41% | −43.41% | −25.95% |
Return on Invested Capital (Normalized) | −24.90% | −42.59% | −29.67% |
Return on Assets
IDYA
PRLD
CGEM
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qnfzglzrj | Hcblp | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Cpxdzzfv | Kqcgwz | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Llswbdw | Qgchz | $98.9 Bil | |
MRNA
| Moderna Inc | Bzqxcxbpt | Ffjh | $39.7 Bil | |
ARGX
| argenx SE ADR | Sjppttlt | Pkbw | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Njmktgr | Ftxdp | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Mtdlhxk | Ccnry | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jvgwthgy | Dchwny | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Fnyvyctsmy | Xrxqqfs | $12.3 Bil | |
INCY
| Incyte Corp | Sktymjnc | Jwpttr | $11.8 Bil |